New pill aims to tame seizures in rare brain disorders
NCT ID NCT07287202
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This early-stage trial tests an oral drug called SVG103 (Paxalisib) in 15 adults with rare brain conditions (FCD-II, TSC, or HME) that cause seizures. The main goal is to check safety and side effects, while also seeing if it reduces seizure frequency. Participants take the drug daily, and the study includes long-term follow-up.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL CORTICAL DYSPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Austin Hospital
RECRUITINGHeidelberg, Victoria, 3084, Australia
-
The Alfred
RECRUITINGMelbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glowing dye could help surgeons spot hidden epilepsy lesions
- Study links gum health to rare kidney diseases
- New drug radiprodil tested for tough seizures in two brain conditions
- Cannabis oil trial aims to tame seizures in rare genetic disorder
- New drug combo targets Hard-to-Treat cancers in early trial
- 20-Year study tests precision medicine for rare Brain-Skin disorders